Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market

The Asia Pacific manufacturing execution system in life sciences market is expected to grow from US$ 834.86 million in 2023 to US$ 2,821.07 million by 2033. It is estimated to grow at a CAGR of 12.9% from 2023 to 2033.

Rising Application in Cell and Gene Therapy Sector Fuels Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market

Cell and gene therapy is one of the growing divisions of the healthcare industry. The growth in the clinical adoption of advanced cell therapy is one of the major factors raising the demand for personalized medicines. In addition, the growing demand for cell therapy and the promise it holds further raise the requirement for MES solutions. It is seen that cell therapy is moving from a manual-oriented lab environment to identifying production scale principles to make the process more robust and error-free with reduced costs. In the cell therapy process, MES can help automate the tracking of the patient’s blood cells through the system and thus offer significant valuable insights for the treatment been manufactured. Furthermore, electronic verification of the process negates human error and can improve a lab's throughput. In addition, the MES solution can also help reduce risk by alerting operators about problems that could have catastrophic consequences. Several market players are also providing MES solutions, particularly for cell and gene manufacturing. For example, POMS Corporation provides POMSnet MES. The MES solution helps regulate industry deliveries such as genealogy, material management, and equipment tracking (instruments, safety hoods, centrifuges, and more). Also, the electronic batch record execution helps manufacturers deliver cell therapies faster by streamlining the production workflow with a cloud-based MES.

There is also an increasing number of collaborations between key solution providers of the pharmaceutical manufacturing industry’s ecosystem for developing advanced solutions for cell and gene therapy product manufacturing. In January 2022, TrakCel, a supplier of cellular orchestration solutions for the cell and gene therapy industry, collaborated with Korber for software integration. The collaboration resulted in a functional integration between TrakCel’s OCELLOS and Korber’s PAS-X. It is expected to allow both companies' cell and gene therapy customers to effectively share data detailing manufacturing events and milestones such as starting checks, fill and finish, and product release; and provide full traceability and audit logs. Thus, the growing application and adoption of MES by the market players in cell and gene therapy manufacturing is expected to create an opportunity for the growth of the manufacturing execution system in life sciences market during the forecast period.

Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market Overview

The MES in life sciences market in Asia Pacific is sub-segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. Various growing economies in the region are witnessing automation in life sciences industries. The healthcare sector in Asia Pacific is flourishing with growth in foreign investments from western countries, especially from Europe and North America. The manufacturing execution systems bring substantial improvements over paper-based processes. They help pharma manufacturers to create flawless manufacturing processes; reduce risks, time, costs, and efforts; and increase process efficiency and product quality. To surpass China in pharma and biotech capabilities, India is continuously substantiating the ecosystem for pharmaceutical manufacturer in the country. Furthermore, the pharmaceutical industry in India is continuously looking for advanced methods to ease manufacturing operations.

Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market Revenue and Forecast to 2033 (US$ Million)

Asia Pacific Manufacturing Execution System (MES) In Life Sciences Strategic Insights

Strategic insights for the Asia Pacific Manufacturing Execution System (MES) In Life Sciences provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Manufacturing Execution System (MES) In Life Sciences Report Scope

Asia Pacific Manufacturing Execution System (MES) In Life Sciences Regional Insights

The geographic scope of the Asia Pacific Manufacturing Execution System (MES) In Life Sciences refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia Pacific Manufacturing Execution System (MES) In Life Sciences Market Segmentation

The Asia Pacific manufacturing execution system in life sciences market is segmented into offering, deployment, organization size, application, and country.

Based on offering, the Asia Pacific manufacturing execution system in life sciences market is segmented into software and services. The services segment held a larger share of the Asia Pacific manufacturing execution system in life sciences market in 2023.

Based on deployment, the Asia Pacific manufacturing execution system in life sciences market is segmented into on-premises and cloud. The cloud segment held a larger share of the Asia Pacific manufacturing execution system in life sciences market in 2023.

Based on organization size, the Asia Pacific manufacturing execution system in life sciences market is segmented into SMEs and large enterprises. The large enterprises segment held the largest share of the Asia Pacific manufacturing execution system in life sciences market in 2023.

Based on application, the Asia Pacific manufacturing execution system in life sciences market is segmented into pharmaceutical, biotechnology, and medical devices. The medical devices segment held the largest share of the Asia Pacific manufacturing execution system in life sciences market in 2023.

Based on country, the Asia Pacific manufacturing execution system in life sciences market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the share of the Asia Pacific manufacturing execution system in life sciences market in 2023.

Atachi Systems; ATS Global B.V.; Emerson Electric Co; LZ Lifescience Limited; Rockwell Automation Inc; Schneider Electric SE; and Siemens AG are the leading companies operating in the Asia Pacific manufacturing execution system in life sciences market.